Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 169

1.

On Don Quixote and pink puffers: multi-organ loss of tissue COPD.

Soriano JB, Burgel PR.

Eur Respir J. 2018 Feb 7;51(2). pii: 1702560. doi: 10.1183/13993003.02560-2017. Print 2018 Feb. No abstract available.

PMID:
29437949
2.

Blood eosinophil counts as a guide for COPD treatment strategies.

Roche N, Zysman M, Burgel PR.

Lancet Respir Med. 2018 Feb;6(2):78-80. doi: 10.1016/S2213-2600(18)30005-5. Epub 2018 Jan 10. No abstract available.

PMID:
29331310
3.

The Major Chromoblastomycosis Etiologic Agent Fonsecaea pedrosoi Activates the NLRP3 Inflammasome.

de Castro RJA, Siqueira IM, Jerônimo MS, Basso AMM, Veloso Junior PHH, Magalhães KG, Leonhardt LC, de Oliveira SAM, Bürgel PH, Tavares AH, Bocca AL.

Front Immunol. 2017 Nov 20;8:1572. doi: 10.3389/fimmu.2017.01572. eCollection 2017.

4.

A simple algorithm for the identification of clinical COPD phenotypes.

Burgel PR, Paillasseur JL, Janssens W, Piquet J, Ter Riet G, Garcia-Aymerich J, Cosio B, Bakke P, Puhan MA, Langhammer A, Alfageme I, Almagro P, Ancochea J, Celli BR, Casanova C, de-Torres JP, Decramer M, Echazarreta A, Esteban C, Gomez Punter RM, Han MK, Johannessen A, Kaiser B, Lamprecht B, Lange P, Leivseth L, Marin JM, Martin F, Martinez-Camblor P, Miravitlles M, Oga T, Sofia Ramírez A, Sin DD, Sobradillo P, Soler-Cataluña JJ, Turner AM, Verdu Rivera FJ, Soriano JB, Roche N; Initiatives BPCO, EABPCO, Leuven and 3CIA study groups.

Eur Respir J. 2017 Nov 2;50(5). pii: 1701034. doi: 10.1183/13993003.01034-2017. Print 2017 Nov.

PMID:
29097431
5.

Staining and Clearing of Arabidopsis Reproductive Tissue for Imaging of Fluorescent Proteins.

Slane D, Bürgel P, Bayer M.

Methods Mol Biol. 2017;1669:87-94. doi: 10.1007/978-1-4939-7286-9_8.

PMID:
28936652
6.

A first step to STOP cystic fibrosis exacerbations.

Burgel PR, Reid DW, Aaron SD.

J Cyst Fibros. 2017 Sep;16(5):529-531. doi: 10.1016/j.jcf.2017.08.006. No abstract available.

PMID:
28865768
7.

Modelling future trends in cystic fibrosis demography using the French Cystic Fibrosis Registry: update and sensitivity analysis.

Burgel PR, Bellis G, Elborn JS.

Eur Respir J. 2017 Aug 3;50(2). pii: 1700763. doi: 10.1183/13993003.00763-2017. Print 2017 Aug. No abstract available.

8.

Harnessing Neutrophil Survival Mechanisms during Chronic Infection by Pseudomonas aeruginosa: Novel Therapeutic Targets to Dampen Inflammation in Cystic Fibrosis.

Marteyn BS, Burgel PR, Meijer L, Witko-Sarsat V.

Front Cell Infect Microbiol. 2017 Jun 30;7:243. doi: 10.3389/fcimb.2017.00243. eCollection 2017. Review.

9.

Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD.

Zysman M, Deslee G, Caillaud D, Chanez P, Escamilla R, Court-Fortune I, Nesme-Meyer P, Perez T, Paillasseur JL, Pinet C, Jebrak G, Roche N, Burgel PR.

Int J Chron Obstruct Pulmon Dis. 2017 Jun 20;12:1819-1824. doi: 10.2147/COPD.S129787. eCollection 2017.

10.

Cystic fibrosis: Current aspects and perspectives.

Burgel PR, Fajac I.

Presse Med. 2017 Jun;46(6 Pt 2):e85-e86. doi: 10.1016/j.lpm.2017.06.001. French. No abstract available.

PMID:
28641709
11.

[Changing patterns of medication prescription for COPD patients in France. Impact of long-acting muscarinic antagonists' availability].

Jébrak G, Burgel PR, Caillaud D, Deslée G, Brinchault G, Chanez P, Court-Fortune I, Escamilla R, Nesme-Meyer P, Pinet C, Perez T, Paillasseur JL, Roche N; pour le groupe Initiatives BPCO.

Rev Mal Respir. 2017 May;34(5):535-543. doi: 10.1016/j.rmr.2017.02.006. Epub 2017 May 31. French.

PMID:
28578989
12.

The changing epidemiology and demography of cystic fibrosis.

Stephenson AL, Stanojevic S, Sykes J, Burgel PR.

Presse Med. 2017 Jun;46(6 Pt 2):e87-e95. doi: 10.1016/j.lpm.2017.04.012. Epub 2017 May 26.

PMID:
28554720
13.

Management of acute exacerbations of chronic obstructive pulmonary disease (COPD). Guidelines from the Société de pneumologie de langue française (summary).

Jouneau S, Dres M, Guerder A, Bele N, Bellocq A, Bernady A, Berne G, Bourdin A, Brinchault G, Burgel PR, Carlier N, Chabot F, Chavaillon JM, Cittee J, Claessens YE, Delclaux B, Deslée G, Ferré A, Gacouin A, Girault C, Ghasarossian C, Gouilly P, Gut-Gobert C, Gonzalez-Bermejo J, Jebrak G, Le Guillou F, Léveiller G, Lorenzo A, Mal H, Molinari N, Morel H, Morel V, Noel F, Pégliasco H, Perotin JM, Piquet J, Pontier S, Rabbat A, Revest M, Reychler G, Stelianides S, Surpas P, Tattevin P, Roche N.

Rev Mal Respir. 2017 Apr;34(4):282-322. doi: 10.1016/j.rmr.2017.03.034. Epub 2017 May 25.

PMID:
28552256
14.

[Impact of acute COPD exacerbation and repetitive episodes on the disease evolution].

Burgel PR.

Rev Mal Respir. 2017 Apr;34(4):331-337. doi: 10.1016/j.rmr.2017.03.003. Epub 2017 May 2. French. No abstract available.

PMID:
28476419
15.

Bacteria-driven peribronchial lymphoid neogenesis in bronchiectasis and cystic fibrosis.

Frija-Masson J, Martin C, Regard L, Lothe MN, Touqui L, Durand A, Lucas B, Damotte D, Alifano M, Fajac I, Burgel PR.

Eur Respir J. 2017 Apr 26;49(4). pii: 1601873. doi: 10.1183/13993003.01873-2016. Print 2017 Apr.

PMID:
28446556
16.

A 3-year prognostic score for adults with cystic fibrosis.

Nkam L, Lambert J, Latouche A, Bellis G, Burgel PR, Hocine MN.

J Cyst Fibros. 2017 Nov;16(6):702-708. doi: 10.1016/j.jcf.2017.03.004. Epub 2017 Mar 18.

17.

Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease.

Hubert D, Chiron R, Camara B, Grenet D, Prévotat A, Bassinet L, Dominique S, Rault G, Macey J, Honoré I, Kanaan R, Leroy S, Desmazes Dufeu N, Burgel PR.

J Cyst Fibros. 2017 May;16(3):388-391. doi: 10.1016/j.jcf.2017.03.003. Epub 2017 Mar 18.

PMID:
28325531
18.

[New therapeutic developments in cystic fibrosis].

Bui S, Macey J, Fayon M; « nouvelles thérapeutiques de la Société Française pour la Mucoviscidose », Bihouée T, Burgel PR, Colomb V, Corvol H, Durieu I, Hubert D, Marguet C, Mas E, Munck A, Murris-Espin M, Reix P, Sermet-Gaudelus I.

Arch Pediatr. 2016 Dec;23(12S):12S47-12S53. doi: 10.1016/S0929-693X(17)30062-3. Review. French.

PMID:
28231894
19.

[Epidemiological trends of cystic fibrosis in France: 10-year perspective].

Burgel PR.

Arch Pediatr. 2016 Dec;23(12S):12S4-12S8. doi: 10.1016/S0929-693X(17)30056-8. Review. French.

PMID:
28231893
20.

Immediate salbutamol responsiveness does not predict long-term benefits of indacaterol in patients with chronic obstructive pulmonary disease.

Burgel PR, Le Gros V, Decuypère L, Bourdeix I, Perez T, Deslée G.

BMC Pulm Med. 2017 Jan 31;17(1):25. doi: 10.1186/s12890-017-0372-z.

21.

How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?

Beeh KM, Burgel PR, Franssen FME, Lopez-Campos JL, Loukides S, Hurst JR, Fležar M, Ulrik CS, Di Marco F, Stolz D, Valipour A, Casserly B, Ställberg B, Kostikas K, Wedzicha JA.

Am J Respir Crit Care Med. 2017 Jul 15;196(2):139-149. doi: 10.1164/rccm.201609-1794CI. Review.

PMID:
27922741
22.

DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis.

Viel M, Hubert D, Burgel PR, Génin E, Honoré I, Martinez B, Gaitch N, Chapron J, Kanaan R, Dusser D, Girodon E, Bienvenu T.

Clin Respir J. 2016 Nov;10(6):777-783. doi: 10.1111/crj.12288. Epub 2015 Apr 15.

PMID:
25763772
23.

A Rapid and Simple Method for Microscopy-Based Stomata Analyses.

Eisele JF, Fäßler F, Bürgel PF, Chaban C.

PLoS One. 2016 Oct 12;11(10):e0164576. doi: 10.1371/journal.pone.0164576. eCollection 2016.

24.

Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients.

Nové-Josserand R, Grard S, Auzou L, Reix P, Murris-Espin M, Brémont F, Mammar B, Mely L, Hubert D, Durieu I, Burgel PR.

Pediatr Pulmonol. 2017 Feb;52(2):190-197. doi: 10.1002/ppul.23612. Epub 2016 Oct 7.

PMID:
27717223
25.

Aspergillus fumigatus in the cystic fibrosis lung: pros and cons of azole therapy.

Burgel PR, Paugam A, Hubert D, Martin C.

Infect Drug Resist. 2016 Sep 20;9:229-238. eCollection 2016. Review.

26.

Impact of current cough on health-related quality of life in patients with COPD.

Deslee G, Burgel PR, Escamilla R, Chanez P, Court-Fortune I, Nesme-Meyer P, Brinchault-Rabin G, Perez T, Jebrak G, Caillaud D, Paillasseur JL, Roche N.

Int J Chron Obstruct Pulmon Dis. 2016 Sep 13;11:2091-2097. eCollection 2016.

27.

Toward Personalized Prescription of Systemic Steroids for Patients Hospitalized With COPD Exacerbations.

Burgel PR.

Chest. 2016 Aug;150(2):268-9. doi: 10.1016/j.chest.2016.03.028. No abstract available.

PMID:
27502977
28.

Asthma-COPD overlap syndrome (ACOS) vs 'pure' COPD: a distinct phenotype?

Caillaud D, Chanez P, Escamilla R, Burgel PR, Court-Fortune I, Nesme-Meyer P, Deslee G, Perez T, Paillasseur JL, Pinet C, Jebrak G, Roche N; Initiatives BPCO scientific committee and investigators.

Allergy. 2017 Jan;72(1):137-145. doi: 10.1111/all.13004. Epub 2016 Sep 27.

PMID:
27501862
29.

Limitations to providing adult cystic fibrosis care in Europe: Results of a care centre survey.

Madge S, Bell SC, Burgel PR, De Rijcke K, Blasi F, Elborn JS; ERS/ECFS task force: The provision of care for adults with cystic fibrosis in Europe.

J Cyst Fibros. 2017 Jan;16(1):85-88. doi: 10.1016/j.jcf.2016.07.001. Epub 2016 Jul 26.

PMID:
27469604
30.

Clinical characteristics, functional respiratory decline and follow-up in adult patients with primary ciliary dyskinesia.

Frija-Masson J, Bassinet L, Honoré I, Dufeu N, Housset B, Coste A, Papon JF, Escudier E, Burgel PR, Maître B.

Thorax. 2017 Feb;72(2):154-160. doi: 10.1136/thoraxjnl-2015-207891. Epub 2016 Jul 5.

PMID:
27382041
31.

Long-term computed tomographic changes in cystic fibrosis patients treated with ivacaftor.

Chassagnon G, Hubert D, Fajac I, Burgel PR, Revel MP; investigators.

Eur Respir J. 2016 Jul;48(1):249-52. doi: 10.1183/13993003.01918-2015. Epub 2016 May 26. No abstract available.

32.

CFTR and/or pancreatitis susceptibility genes mutations as risk factors of pancreatitis in cystic fibrosis patients?

Gaitch N, Hubert D, Gameiro C, Burgel PR, Houriez F, Martinez B, Honoré I, Chapron J, Kanaan R, Dusser D, Girodon E, Bienvenu T.

Pancreatology. 2016 Jul-Aug;16(4):515-22. doi: 10.1016/j.pan.2016.03.021. Epub 2016 Apr 5.

PMID:
27086061
33.

Exacerbations of COPD.

Pavord ID, Jones PW, Burgel PR, Rabe KF.

Int J Chron Obstruct Pulmon Dis. 2016 Feb 19;11 Spec Iss:21-30. doi: 10.2147/COPD.S85978. eCollection 2016. Review.

34.

[Small airway diseases and immune deficiency].

Burgel PR, Bergeron A, Knoop C, Dusser D.

Rev Mal Respir. 2016 Feb;33(2):145-55. doi: 10.1016/j.rmr.2015.11.003. Epub 2016 Feb 4. Review. French.

PMID:
26854188
35.

[Demographic growth and targeted therapies: The changing face of cystic fibrosis].

Fajac I, Burgel PR.

Rev Mal Respir. 2016 Oct;33(8):645-647. doi: 10.1016/j.rmr.2015.12.001. Epub 2016 Jan 6. French. No abstract available.

PMID:
26777401
36.

Primary ciliary dyskinesia in adults.

Honoré I, Burgel PR.

Rev Mal Respir. 2016 Feb;33(2):165-89. doi: 10.1016/j.rmr.2015.10.743. Epub 2015 Dec 1. Review.

PMID:
26654126
37.

Neutrophil-Expressed p21/waf1 Favors Inflammation Resolution in Pseudomonas aeruginosa Infection.

Martin C, Ohayon D, Alkan M, Mocek J, Pederzoli-Ribeil M, Candalh C, Thevenot G, Millet A, Tamassia N, Cassatella MA, Thieblemont N, Burgel PR, Witko-Sarsat V.

Am J Respir Cell Mol Biol. 2016 May;54(5):740-50. doi: 10.1165/rcmb.2015-0047OC.

PMID:
26517580
38.

Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis.

Elborn JS, Bell SC, Madge SL, Burgel PR, Castellani C, Conway S, De Rijcke K, Dembski B, Drevinek P, Heijerman HG, Innes JA, Lindblad A, Marshall B, Olesen HV, Reimann AL, Solé A, Viviani L, Wagner TO, Welte T, Blasi F.

Eur Respir J. 2016 Feb;47(2):420-8. doi: 10.1183/13993003.00592-2015. Epub 2015 Oct 9.

39.

Renin-associated hypertension after bronchial artery embolization in cystic fibrosis.

Coolen N, Gouya H, Kanaan R, Honoré I, Chapron J, Hubert D, Legmann P, Dusser D, Burgel PR.

J Cyst Fibros. 2016 Mar;15(2):213-5. doi: 10.1016/j.jcf.2015.09.003. Epub 2015 Sep 26.

PMID:
26412053
40.

Causes of death in French cystic fibrosis patients: The need for improvement in transplantation referral strategies!

Martin C, Hamard C, Kanaan R, Boussaud V, Grenet D, Abély M, Hubert D, Munck A, Lemonnier L, Burgel PR.

J Cyst Fibros. 2016 Mar;15(2):204-12. doi: 10.1016/j.jcf.2015.09.002. Epub 2015 Sep 26.

PMID:
26391389
41.

Modified Medical Research Council scale vs Baseline Dyspnea Index to evaluate dyspnea in chronic obstructive pulmonary disease.

Perez T, Burgel PR, Paillasseur JL, Caillaud D, Deslée G, Chanez P, Roche N; INITIATIVES BPCO Scientific Committee.

Int J Chron Obstruct Pulmon Dis. 2015 Aug 18;10:1663-72. doi: 10.2147/COPD.S82408. eCollection 2015.

42.

Turning Up the Heat: Inflammasome Activation by Fungal Pathogens.

Tavares AH, Bürgel PH, Bocca AL.

PLoS Pathog. 2015 Jul 23;11(7):e1004948. doi: 10.1371/journal.ppat.1004948. eCollection 2015 Jul. Review. No abstract available.

43.

United airway diseases. Should we add upper airway inflammatory disorders to the list of chronic obstructive pulmonary disease comorbidities?

Burgel PR.

Ann Am Thorac Soc. 2015 Jul;12(7):968-70. doi: 10.1513/AnnalsATS.201505-309ED. No abstract available.

PMID:
26203605
44.

An official American Thoracic Society/European Respiratory Society statement: research questions in COPD.

Celli BR, Decramer M, Wedzicha JA, Wilson KC, Agustí AA, Criner GJ, MacNee W, Make BJ, Rennard SI, Stockley RA, Vogelmeier C, Anzueto A, Au DH, Barnes PJ, Burgel PR, Calverley PM, Casanova C, Clini EM, Cooper CB, Coxson HO, Dusser DJ, Fabbri LM, Fahy B, Ferguson GT, Fisher A, Fletcher MJ, Hayot M, Hurst JR, Jones PW, Mahler DA, Maltais F, Mannino DM, Martinez FJ, Miravitlles M, Meek PM, Papi A, Rabe KF, Roche N, Sciurba FC, Sethi S, Siafakas N, Sin DD, Soriano JB, Stoller JK, Tashkin DP, Troosters T, Verleden GM, Verschakelen J, Vestbo J, Walsh JW, Washko GR, Wise RA, Wouters EF, ZuWallack RL; ATS/ERS Task Force for COPD Research.

Eur Respir Rev. 2015 Jun;24(136):159-72. doi: 10.1183/16000617.00000315. Review.

45.

An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease.

Celli BR, Decramer M, Wedzicha JA, Wilson KC, Agustí A, Criner GJ, MacNee W, Make BJ, Rennard SI, Stockley RA, Vogelmeier C, Anzueto A, Au DH, Barnes PJ, Burgel PR, Calverley PM, Casanova C, Clini EM, Cooper CB, Coxson HO, Dusser DJ, Fabbri LM, Fahy B, Ferguson GT, Fisher A, Fletcher MJ, Hayot M, Hurst JR, Jones PW, Mahler DA, Maltais F, Mannino DM, Martinez FJ, Miravitlles M, Meek PM, Papi A, Rabe KF, Roche N, Sciurba FC, Sethi S, Siafakas N, Sin DD, Soriano JB, Stoller JK, Tashkin DP, Troosters T, Verleden GM, Verschakelen J, Vestbo J, Walsh JW, Washko GR, Wise RA, Wouters EF, ZuWallack RL; ATS/ERS Task Force for COPD Research.

Am J Respir Crit Care Med. 2015 Apr 1;191(7):e4-e27. doi: 10.1164/rccm.201501-0044ST.

PMID:
25830527
46.

An official American Thoracic Society/European Respiratory Society statement: research questions in COPD.

Celli BR, Decramer M, Wedzicha JA, Wilson KC, Agustí A, Criner GJ, MacNee W, Make BJ, Rennard SI, Stockley RA, Vogelmeier C, Anzueto A, Au DH, Barnes PJ, Burgel PR, Calverley PM, Casanova C, Clini EM, Cooper CB, Coxson HO, Dusser DJ, Fabbri LM, Fahy B, Ferguson GT, Fisher A, Fletcher MJ, Hayot M, Hurst JR, Jones PW, Mahler DA, Maltais F, Mannino DM, Martinez FJ, Miravitlles M, Meek PM, Papi A, Rabe KF, Roche N, Sciurba FC, Sethi S, Siafakas N, Sin DD, Soriano JB, Stoller JK, Tashkin DP, Troosters T, Verleden GM, Verschakelen J, Vestbo J, Walsh JW, Washko GR, Wise RA, Wouters EF, ZuWallack RL; ATS/ERS Task Force for COPD Research.

Eur Respir J. 2015 Apr;45(4):879-905. doi: 10.1183/09031936.00009015. Review.

47.

Future trends in cystic fibrosis demography in 34 European countries.

Burgel PR, Bellis G, Olesen HV, Viviani L, Zolin A, Blasi F, Elborn JS; ERS/ECFS Task Force on Provision of Care for Adults with Cystic Fibrosis in Europe.

Eur Respir J. 2015 Jul;46(1):133-41. doi: 10.1183/09031936.00196314. Epub 2015 Mar 18.

48.

Chronic obstructive pulmonary disease phenotypes. Past, present, and future.

Burgel PR, Sethi S, Kim V.

Ann Am Thorac Soc. 2015 Mar;12(3):289-90. doi: 10.1513/AnnalsATS.201501-011ED. No abstract available.

PMID:
25786144
49.

Reduced risk of nontuberculous mycobacteria in cystic fibrosis adults receiving long-term azithromycin.

Coolen N, Morand P, Martin C, Hubert D, Kanaan R, Chapron J, Honoré I, Dusser D, Audureau E, Veziris N, Burgel PR.

J Cyst Fibros. 2015 Sep;14(5):594-9. doi: 10.1016/j.jcf.2015.02.006. Epub 2015 Feb 28.

50.

Host-microbe interactions in distal airways: relevance to chronic airway diseases.

Martin C, Burgel PR, Lepage P, Andréjak C, de Blic J, Bourdin A, Brouard J, Chanez P, Dalphin JC, Deslée G, Deschildre A, Gosset P, Touqui L, Dusser D.

Eur Respir Rev. 2015 Mar;24(135):78-91. doi: 10.1183/09059180.00011614. Review.

Supplemental Content

Loading ...
Support Center